← Back to Search

Procedure

Magnetic Seizure Therapy (MST) for Schizophrenia (MAST Trial)

N/A
Waitlist Available
Led By Daniel Blumberger, M.D., MSc.
Research Sponsored by Centre for Addiction and Mental Health
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
1. are inpatients or outpatients;
2. demonstrate capacity to consent according to the MacArthur competence assessment tool for clinical research (MacCAT-CR);
Timeline
Screening 3 weeks
Treatment Varies
Follow Up greater than 8 treatments (2.5 weeks)
Awards & highlights
No Placebo-Only Group

Summary

This trial aims to assess the clinical effects and tolerability of Magnetic Seizure Therapy (MST) as an alternative to electroconvulsive therapy (ECT) for Treatment Resistant Schizophrenia (RS).

Who is the study for?
This trial is for individuals with Treatment Resistant Schizophrenia, meaning their condition hasn't improved after trying other treatments. Participants should be able to undergo procedures like Magnetic Seizure Therapy (MST) or Electroconvulsive Therapy (ECT).
What is being tested?
The study compares the effectiveness and tolerability of two treatments: Magnetic Seizure Therapy (MST) and Electroconvulsive Therapy (ECT), in patients who have not responded well to standard schizophrenia therapies.
What are the potential side effects?
Possible side effects may include confusion, memory problems, headaches, muscle aches or discomfort at the site of treatment. These are common to seizure-inducing therapies but can vary between MST and ECT.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~greater than 8 treatments (2.5 weeks)
This trial's timeline: 3 weeks for screening, Varies for treatment, and greater than 8 treatments (2.5 weeks) for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Brief Psychiatric Rating Scale (BPRS) Response (18-Version)
MATRICS™ Consensus Cognitive Battery (MCCB)
Secondary study objectives
Autobiographical Memory Test (AMT)
Montreal Cognitive Assessment (MoCA)
Scale for Suicidal Ideation (SSI)
+1 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Magnetic Seizure Therapy (MST)Experimental Treatment1 Intervention
MST treatments will be administered using the MagPro MST with Cool TwinCoil.
Group II: Electroconvulsive Therapy (ECT)Active Control1 Intervention
ECT treatments will be administered using the MECTA spECTrum 5000Q or MECTA Sigma.

Find a Location

Who is running the clinical trial?

Centre for Addiction and Mental HealthLead Sponsor
370 Previous Clinical Trials
83,132 Total Patients Enrolled
59 Trials studying Schizophrenia
4,231 Patients Enrolled for Schizophrenia
University of British ColumbiaOTHER
1,466 Previous Clinical Trials
2,485,497 Total Patients Enrolled
15 Trials studying Schizophrenia
1,449 Patients Enrolled for Schizophrenia
Daniel Blumberger, M.D., MSc.Principal InvestigatorCentre for Addiction and Mental Health
~53 spots leftby Nov 2028
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top